CANDIDATES FOR THERAPY Percutaneous Tibial Neuromodulation (PTNM)
For some overactive bladder (OAB) patients, pharmacology is adequate. However, as many as 7 in 10 patients give up taking medication within 6 months.1,2 Patient compliance with medications such as anticholinergics is low due to variable efficacy and side effects, such as dry mouth and constipation.3
PTNM, delivered by the Medtronic NURO™ System, expands your treatment options for OAB patients who:
Third-line OAB treatment options include:
BOTOX® is a registered trademark of Allergan, Inc.
Haab, F. and D. Castro-Diaz (2005). Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59(8): 931-937.
Yeaw, J., J. S. Benner, et al. (2009). Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15(9): 728-740.
Gormley, E. A., D. J. Lightner, et al. (2015). Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5): 1572-1580.